METHODS OF ENHANCING ANTI-TUMOUR IMMUNITY IN A MAMMAL

Anti-tumour immune responses are elicited by engineering genetically lymphom a tumour cells to express interleukin- 12 (IL- 12), the combination of B7-1 an d interleukin- 12, or by increasing endogenous expression of the costimulatory molecule B7-2. T he combination of B7-1 and IL-12 is most effecti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	PIZZOFERRATO, EVA
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Anti-tumour immune responses are elicited by engineering genetically lymphom a tumour cells to express interleukin- 12 (IL- 12), the combination of B7-1 an d interleukin- 12, or by increasing endogenous expression of the costimulatory molecule B7-2. T he combination of B7-1 and IL-12 is most effective in minimal disease settings when the tumour cell engineered genetically to express both molecules is inoculated into the same site of tumour burden. In addition, increasing the expression of endogenous B7-2 provides another method by which anti-tumour immunity is generated against unmodified tumour cells. The mechanisms of the anti-tumour immune response are multifactorial involving T cells as well as natural killer (NK) cells.